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Abstract
Natively disordered proteins are a growing class of anomalies to the structure–function paradigm. The
natively disordered protein a-synuclein is the primary component of Lewy bodies, the cellular hall-
mark of Parkinson’s disease. We noticed a dramatic difference in dilute solution 1H-15N Hetero-
nuclear Single Quantum Coherence (HSQC) spectra of wild-type a-synuclein and two disease-related
mutants (A30P and A53T), with spectra collected at 35C showing fewer cross-peaks than spectra
acquired at 10C. Here, we show the change to be the result of a reversible conformational exchange
linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised.
Combined with analytical ultracentrifugation data showing a-synuclein to be monomeric at both
temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35C is due
to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated
variant of a-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the
protein. Our data illustrate a key difference between globular and natively disordered proteins. The
properties of globular proteins change little with solution conditions until they denature cooperatively,
but the properties of natively disordered proteins can vary dramatically with solution conditions.
Keywords: 1H-15N heteronuclear single quantum coherence (HSQC); hydrodynamic radius; natively
disordered proteins; Parkinson’s disease; pulsed-field gradient NMR; a-synuclein
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Parkinson’s disease affects over one million North Amer-
icans, and occurs in ,3% of the population over the
age of 65 (Lang and Lozano 1998). Symptoms of rigidity,
tremor, and loss of motor function result primarily from
the loss of dopaminergic neurons in the substantia nigra
(Hirsch 1992). Histologically, the hallmark of Parkinson’s
disease is the formation of intracellular protein aggregates
called Lewy bodies (Galloway et al. 1992). While proteins
such as tau, cytochrome c, and parkin are also found in
Lewy bodies, the primary component is the protein, a-
synuclein (Spillantini et al. 1997).
a-Synuclein belongs to an enigmatic class called na-
tively disordered proteins, which lack stable tertiary
structure in dilute solution. The stable tertiary structure
of globular proteins is the scaffolding for their biological
functions (Daughdrill et al. 2004). Chemical groups
appended to these rigid scaffolds enact the specific and
tight binding of ligands for signal transduction and
transition states for catalysis. This protein structure–
function paradigm is over 70 years old (Mirsky and
Pauling 1936; Edsall 1995), but the recent realization
that natively disordered proteins function without ter-
tiary structure is adding new excitement to protein chem-
istry (Daughdrill et al. 2004).
a-Synuclein is a small cytosolic protein commonly
found at the presynaptic terminals of dopaminergic
neurons, and is implicated in neuronal plasticity and neu-
rotransmitter release (Jakes et al. 1994; George et al. 1995;
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Wersinger et al. 2003). This 140-amino-acid (14.4 kDa)
protein contains three main regions (Maroteaux et al.
1988). The N-terminal region (residues 1–60) contains six
imperfect KTKEGV repeats and three disease-associated
mutations A30P, E46K, and A53T (Polymeropoulos et al.
1997; Krüger et al. 1998; Zarranz et al. 2004). The middle
region (residues 61–95), called the nonamyloid component
(NAC), is hydrophobic and flexible. These two regions
gain a-helical structure in the presence of synthetic lip-
id vesicles or sodium dodecyl sulfate (SDS) micelles
(Chandra et al. 2003; Bussell and Eliezer 2004). The C-
terminal region (residues 95–140) has an excess of nega-
tively charged residues and does not gain stable structure
on binding vesicles (Bussell and Eliezer 2004). Recently,
the interaction of the C-terminal region with the N termi-
nus and NAC region has been shown to slow aggregation
in vitro (Murray et al. 2003; Dedmon et al. 2004; Hoyer
et al. 2004; Bertoncini et al. 2005; Li et al. 2005).
a-Synuclein collapses in the presence of 1 M glucose
(Morar et al. 2001), and its aggregation accelerates in
vitro in stirred solutions crowded with proteins, poly-
saccharides, or polyethylene glycols (Shtilerman et al.
2002; Uversky et al. 2002; Goers et al. 2003). Addition-
ally, a-synuclein gains secondary structure in the pres-
ence of trimethylamine-N-oxide (Uversky et al. 2001b).
Lipid vesicles or SDS micelles increase the a-helical
content of a-synuclein (Chandra et al. 2003; Bussell
and Eliezer 2004; Bisaglia et al. 2005), but decrease its
rate of aggregation (Zhu and Fink 2003). Recently, it
was shown that the helical content a-synuclein depends
on micelle size (Ulmer et al. 2005); lipid-vesicle bound a-
synuclein forms one large a-helix comprising the first
100 residues (Eliezer et al. 2001), but the SDS micelle-
bound species forms two shorter a-helices connected by
a well-ordered 7-amino-acid linker (Ulmer et al. 2005).
Here, we explore the effects of the simplest perturbant,
temperature, on the conformation of a-synuclein.
Results
Full-length -synuclein
Figure 1 shows three consecutive 17-h 1H-15N HSQC
experiments (total time, 51 h) conducted on a single 1
mM a-synuclein sample. Seventeen hours was selected
so the data can be directly compared to our in-cell
NMR data (McNulty et al. 2006). The spectra were
contoured identically. Figure 1A shows the spectrum
acquired at 10C between hours 0 and 17. Figure 1B
shows the spectrum of the same sample at 35C col-
lected between hours 17 and 34. Figure 1C shows the
third experiment conducted between hours 34 and 51 at
10C. Data for the two variants are located in the
supplemental material.
The number of cross-peaks observed depends upon
temperature. The 10C spectrum (Fig. 1A) has ,72
backbone cross-peaks. The 35C spectrum (Fig. 1B)
only has ,32 backbone cross-peaks. The long acquisi-
tion time would have allowed us to detect even weak
cross-peaks had they been present. Although many
Figure 1.
1H-15N HSQC spectra of three consecutive 17-h experiments
(total time, 51 h) on a single 1 mM sample of a-synuclein (20 mM
sodium phosphate at pH 7.4). The glycine region is indicated by a black
arrow and the threonine region is indicated by a white arrow. The first
spectrum (A) was acquired between hours 0 and 17 at 10C. The second
spectrum (B) was acquired between hours 17 and 34 at 35C. The third
spectrum (C) was acquired between hours 34 and 51 at 10C.
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cross-peaks disappear at 35C, the cross-peak heights,
positions, and volumes of the second 10C spectrum
(Fig. 1C) are equivalent to those for the first 10C spec-
trum (Fig. 1A). In summary, 1H-15N HSQC spectra of
a-synuclein in dilute solution changes with temperature,
and that change is reversible.
The narrow distribution of the cross-peaks in the 1H
dimension in Figure 1A suggests a-synuclein is natively
disordered or in a PII helix (Lam and Hsu 2003) at 10C.
The spectrum is unlike that of a-synuclein in the pres-
ence of SDS micelles, which shows more cross-peak dis-
persion in the 1H dimension and is indicative of its a-
helical structure (Chandra et al. 2003).
The most striking differences between the 10C and
35C spectra occur in the regions containing glycine and
threonine cross-peaks (8.2–8.6 ppm in the 1H dimension
and 107–117 ppm in the 15N dimension). The spectrum
shown in Figure 1A is so similar to a previously pub-
lished assigned spectrum (Eliezer et al. 2001) that we
were able to use the assignments directly. Comparing
our data with published assignments, the cross-peaks
that disappear at 35C correspond to the first 100 resi-
dues of a-synuclein. As temperature increases from 10C
to 25C (data not shown) to 35C, cross-peak heights
and volumes decrease for the N-terminal 100 residues,
but remain constant for the C-terminal 40 residues (data
not shown). The loss of N-terminal cross-peaks at 35C
could be caused by temperature induced conformational
exchange of monomeric a-synuclein or by aggregation.
To assess the aggregation state, we performed sedi-
mentation equilibrium experiments at the same a-synu-
clein concentration used for the NMR experiments (Fig.
2). The apparent molecular weight of a-synuclein at
both temperatures is consistent with the presence of
monomeric a-synuclein (14.4 kDa at 10C and 13.3
kDa at 35C). The lower molecular weight for the data
in Figure 2B is the result of Donnan nonideality (Roark
and Yphantis 1971; Krishnan et al. 2003). We conclude
the loss of cross-peaks in the 1H-15N HSQC at 35C
reflects conformational exchange on the time scale of
the 1H chemical shifts.
Pulsed-field gradient studies show the hydrodynamic
radius of a-synuclein increases 7.36 1.1 Å, from 23.16 0.6
Å to 31.46 0.9 Å upon increasing the temperature from
10C to 35C. Importantly, the radius returns to 23 Å
when the temperature is decreased again to 10C, fur-
ther confirming the reversibility of the conformational
change.
Truncated -synuclein
We repeated the 1H-15N HSQC experiments presented
above with a-synuclein-100, a truncated variant compris-
ing residues 1–100. Figure 3 shows three consecutive 17-h
1H-15NHSQC experiments (total time, 51 h) conducted on
a single 500-mM a-synuclein-100 sample. The spectra were
contoured identically. Figure 3A shows the spectrum
acquired at 10C. Figure 3B shows the spectrum of the
same sample at 35C. Figure 3C shows the third experi-
ment conducted at 10C. As in the full-length NMR
experiment, the cross-peak heights, positions, and volumes
are equivalent in the two 10C spectra (Fig. 3A,C). Addi-
tionally, almost all of the cross-peaks present at 10C
disappear at 35C, further supporting our conclusion that
the conformational exchange occurs in the first 100 amino
acids of the full-length protein. In summary, the similari-
ties between the spectra show that the absence of the C-
terminal 40 residues does not drastically affect the ensem-
ble of conformations accessible to the first 100 residues.
Discussion
We noticed a discrepancy among the published dilute solu-
tion 1H-15NHSQCNMRspectra ofa-synuclein (Eliezer et
al. 2001;Chandra et al. 2003;Bussell andEliezer 2004).This
discrepancy appeared to result from a difference in tem-
perature at which the data were acquired. Specifically,
spectra contain more cross-peaks at 10C (Eliezer et al.
2001; Bussell and Eliezer 2004) than at 25C (Chandra et
al. 2003). To confirm this difference, we performed a three-
Figure 2. Equilibrium analytical ultracentrifugation data acquired at
293 nm for 1 mM wild-type a-synuclein at 10C (A) and 35C (B).
Molecular weights of 14.4 kDa and 13.3 kDa were obtained at 10C
and 35C, respectively.
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stage (10C, 35C, 10C) dilute solution experiment on a
single sample of a-synuclein. This experiment (Fig. 1) re-
produces the spectra of Bussell and Eliezer (Eliezer et al.
2001; Bussell and Eliezer 2004) and Chandra et al. (2003).
The identity in cross-peak positions, and volumes for the
two 10C spectra in the 10–35–10C series (Fig. 1A,C)
prove the temperature-induced change is reversible.
What causes this reversible change in the HSQC spec-
tra? Analytical ultracentrifugation data (Fig. 2) show the
protein is a monomer at both temperatures, ruling out
aggregation as the cause. Using circular dichroism spec-
tropolarimetry (CD), Uversky et al. (2001a) showed that
a-synuclein gains secondary structure, most likely a-
helix, with increasing temperature. Repeating these ex-
periments (data not shown), we observed the same
increase in secondary structure upon increasing the
temperature from 10C to 35C and that the increase is
reversible. Therefore, the change coincides with a gain in
secondary structure of monomeric a-synuclein.
Next, we identified the regions of a-synuclein associated
with the change in HSQC spectrum at 35C. As shown by
comparing spectra for the full-length protein (Fig. 1) with
spectra from truncated a-synuclein (Fig. 3), the cross-
peaks that disappear at 35C are from the N-terminal 100
residues. Spectra acquired at temperatures between 10C
and 35C exhibit decreased cross-peak volumes for the 100
N-terminal residues, but cross-peak location remains con-
stant (data not shown). Cross-peaks from the C-terminal
40 residues are present at all temperatures studied, and
their volume and location are independent of temperature.
From these observations, we conclude the region under-
going intermediate exchange at 35C comprises the N-
terminal 100 amino acids, while the last 40 residues remain
highly dynamic at all temperatures studied.
This conclusion is also supported by the work of
others. The HSQC spectrum obtained at 35C (Fig. 1B)
is similar to that of lipid vesicle associated a-synuclein,
in terms of cross-peak number, cross-peak position,
and the residues represented—all from the C-terminal 40
amino acids (Eliezer et al. 2001; Dedmon et al. 2002;
Bussell and Eliezer 2004). Furthermore, the N-terminal
100 amino acid residues gain a-helical structure when a-
synuclein binds to lipid vesicles (Eliezer et al. 2001)
and SDS micelles (Chandra et al. 2003).
The disappearance of crosspeaks from the first 100
residues at 35C could also be caused by increased
amide–1H exchange, but several additional observa-
tions favor conformational exchange. First, estimates
of amide 1H exchange rates with the computer program
SPHERE (www.fccc.edu/research/labs/roder/sphere/) show
no obvious pattern to suggest much greater exchange
in the N-terminal portion of the protein. Second, it is
unlikely that the increase in structure at 35C noted
above would lead to increased amide–1H exchange.
The reverse is more likely. Third, resonances from the
C-terminal end persist at the higher temperature. The C-
terminal end of the protein remains unstructured under
all conditions tested so far. Lack of structure maximizes
amide–1H exchange, yet we see cross-peaks from this
region of the protein. Taken together, these observations
argue that the absence of cross-peaks is the result of
Figure 3. 1H-15N HSQC spectra of three consecutive 17-h experiments
(total time, 51 h) on a single 1-mM sample of the truncated variant a-
synuclein-100 (20 mM sodium phosphate at pH 7.4). The first spectrum
(A) was acquired between hours 0 and 17 at 10C. The second spectrum
(B) was acquired between hours 17 and 34 at 35C. The third spectrum
(C) was acquired between hours 34 and 51 at 10C.
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conformational exchange on the chemical shift time-
scale, not amide–1H exchange.
From our NMR, AUC, and CD studies, along with
the work of others, we conclude that the N-terminal 100
amino acids of a-synuclein undergoes intermediate
conformational exchange at 35C. In other words, the
difference in chemical shift between the various confor-
mations within the ensemble at 35C is approximate-
ly equal to the rate of exchange between the conformations.
This exchange results in the disappearance of cross-
peaks from the N-terminal region for spectra collected
at 35C.
We also characterized the ensembles present at 10C
and 35C. At 10C, the limited chemical shift dispersion
of cross-peaks in the 1H dimension (Fig. 1A,C) shows
that a-synuclein is disordered. The pulsed-field gradient
NMR data show the disordered ensemble is collapsed
at 10C. In fact, the hydrodynamic radius at 10C,
21.36 0.6 Å, is only 2 Å larger than that expected for a
native globular protein the size of a-synuclein (Wilkins
et al. 1999).
The ensemble expands in hydrodynamic radius as the
temperature is increased. The radius increases to 27 Å at
25C (Morar et al. 2001) and to 31.46 0.9 Å at 35C.
Since it is the N-terminal region that switches to inter-
mediate exchange at 35C, we conclude that this region
plays a key role in the expansion.
In summary, we have shown the N-terminal two-
thirds of the natively disordered protein a-synuclein
expands and undergoes conformational exchange on
the intermediate time scale as the temperature is raised
from 10C to 35C. The collapsed ensemble present at
10C is disordered, but the N-terminal two-thirds of the
protein expands because it gains a-helical structure upon
increasing the temperature to 35C.
Such a small change in temperature would have an
insignificant effect on most globular proteins. Our data
highlight the idea that natively disordered proteins
are exquisitely sensitive to their environment (Uversky
2003), and the biological significance of what we learn
from studies of natively disordered proteins hinges on our
choice of solution conditions. Finally, the similarities
between the HSQC spectrum of the protein in living
cells at 35C (McNulty et al. 2006) and the spectrum in
dilute solution at 10C suggest that more biologically
relevant information about a-synuclein might be
obtained by studying the protein in vitro at 10C.
Materials and methods
Purification of -synuclein
Escherichia coli BL-21 (DE3-Gold) cells (Stratagene) were
transformed with the pT7–7 plasmid containing the a-synu-
clein gene (supplied by Dr. Peter Lansbury) and spread on Luria
broth agar plates with 100 mg/mL ampicillin (LBAmp). A single
colony was added to 250 mL of LBAmp, and the culture was
grown in a rotary shaker (225 rpm) for 16 h at 37C.
Fifteen milliliters of the overnight culture were transferred to
250 mL of LBAmp and grown in a rotary shaker (225 rpm) at
37C to an OD600 nm of 0.4–0.6. Cultures were then centrifuged
(Sorvall RC-5B with a SS-34 rotor) at 3000 rpm for 30 min at
4C. Cell pellets were resuspended in 250 mL of M9 minimal
media (Serber et al. 2001) containing 100 mg/mL 15NH4Cl,
induced with isopropyl b-D-thiogalactopyranoside to a final
concentration of 1 mM and grown in a rotary shaker (225 rpm)
at 37C for 4 h. Cell cultures were centrifuged at 5000 rpm for
30 min at 4C.
The cell pellet was resuspended in 25 mL of lysis buffer (10
mM Tris at pH 8.0, 1 mM ethylenediaminetetraacetic acid, 1
mM phenylmethanesulfonyl fluoride, 1 mM 1,4-dithio-L-threi-
tol, with a few crystals of RNase, DNase, and lysozyme). The
cell lysate was sonicated (Gallenkamp Soniprep 150) continu-
ously for 10 min, boiled for 20 min, and then centrifuged at
15,000 rpm for 30 min at 4C. The resulting supernatant was
again boiled for 20 min and centrifuged at 15,000 rpm for 30
min at 4C. The final supernatant was subjected to (NH4)2SO4
precipitation (361 g/L) and centrifuged at 15,000 rpm for 30
min at 4C.
The pellet was resuspended in 20 mM sodium phosphate
buffer (pH 7.4), and dialyzed against the same buffer for 5 h at
4C. The protein was further purified by anion exchange chro-
matography (ÄKTA FPLC UPC-900, Q-10 column, Amersham
Pharmacia Biotech) with a 1-M NaCl linear gradient at 4C.
The fractions containing a-synuclein were pooled and dialyzed
against the original buffer for 24 h at 4C. The dialyzed a-
synuclein was concentrated to 1.1 mM in a YM-3 Centricon
filter (Millipore, MWCO 3500) at 10C. The purity of the
protein was assessed by using SDS-PAGE with Coomassie bril-
liant blue staining. Purified a-synuclein was stored at -80C.
Purification of -synuclein truncated
at residue 100 (-synuclein-100)
Cells containing 15N-enriched a-synuclein-100 were produced
using the methodology described for the full-length protein,
but purification differed slightly. The boiling and centrifuga-
tion steps were performed only once; subsequent purification
steps were performed on ice, and cation exchange chromatog-
raphy (SP-16/10 column, Amersham Pharmacia Biotech) was
performed at 4C with a 1-M NaCl linear gradient.
Heteronuclear NMR
Samples for dilute solution spectra comprised a 90:10 mixture
of pure 1.1 mM a-synuclein solution:D2O in a Shigemi tube.
1H-15N HSQC spectra were acquired at the UNC Biomolecular
NMR facility on a Varian 600-MHz NMR spectrometer,
equipped with a Triax triple resonance probe for (1H sweep
width: 6999 Hz; 15N sweep width: 2100 Hz, 196 transients and
128 increments). Each spectrum required 17 h. For reversibility
experiments, three sequential 1H-15N HSQC spectra (196 tran-
sients, 128 increments) were acquired on the same sample at
10C, at 35C and again at 10C over the course of 52 h. Data
were processed and visualized with NMRPipe and NMRDraw,
respectively (Delaglio et al. 1995).
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Pulsed-field gradient NMR
Spectra were acquired on the spectrometer described above.
To replace exchangeable protons with deuterons, pure 1.1
mM a-synuclein samples were diluted threefold with 100%
D2O and concentrated in an Amicon filter (MWCO: 3500) at
4C. To ensure complete exchange, this process was per-
formed three times more. The final concentration of a-synu-
clein was 1.1 mM. We used dioxane as the hydrodynamic
radius standard (Wilkins et al. 1999), at a final concentration
of 1 mM. Three sequential pulsed-field gradient experiments
were conducted as previously described (Morar et al. 2001) on
a single sample at 10C, at 35C and again at 10C with a few
alterations. The recycle delay was 2 s, there were 256 scans
and each experiment took 6 h. Once the radius change was
shown to be reversible, additional experiments were con-
ducted at either 10C or 35C to increase the number of
replicates used to obtain the mean and standard error. Data
were processed and visualized with Varian’s VNMRJ (Ver-
sion 1.1C).
Analytical ultracentrifugation (AUC)
Sedimentation equilibrium experiments were carried out at
the UNC Macromolecular Interactions Facility on a Beckman
XL-I ultracentrifuge. The samples were spun at 20,000 rpm
for 20 h. Absorbance was monitored at 293 nm every 2 h.
Separate experiments were conducted at 10C and 35C.
a-Synuclein samples ranged in concentration from 0.2 mM
to 1 mM. Equilibrium was assumed to have been reached
when two consecutive scans gave identical absorption profiles.
The absorbance offset was determined by the meniscus
depletion method after a 6-h overspeed run at 45,000 rpm.
Site-directed mutagenesis
The A30P and A53T mutants were generated with a Stratagene







The sequences of the mutants were verified at the UNC-CH
Genome Analysis facility with the primer: 5¢-GGGAGACCAC
AACGGTTTCCCTCTAG-3¢.
A truncated variant of a-synuclein, comprising amino acids
1–100 (a-synuclein-100), was generated by inserting a prema-
ture stop codon with a Stratagene site-directed mutagenesis
kit by using the following primers: Syn100-FWD 5¢-TTGTC
AAAAAGGACCAGTAGGGCAAGAATGAAGAAGG-3¢;
Syn 100-REV5¢-CCTTCTTCATTCTTGCCCTACTGGTCCTT
TTTGACAA-3¢. The sequence of the truncated variant was veri-
fied as described above.
Electronic supplemental material
Figures 4 and 5 show the 1H-15N HSQC spectra of the A30P
and A53T variants collected at 10C, 35C, and again at 10C.
The figures show how the two disease-related variants exhibit
the same temperature-induced behavior as the wild-type protein.
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